|
| | Publication Year | Title | Author(s) |
| 661 | 19-Jan-2018 | Personalized chemosensitivity assays for mesothelioma- is it worth the effort? | John, Thomas ; Chia, Puey Ling |
| 2 | 1-Apr-2018 | Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort? | John, Thomas ; Chia, Puey Ling |
| 3 | Dec-2018 | Perspective: cancer vaccines in the era of immune checkpoint blockade. | Cebon, Jonathan S |
| 4 | 20-Dec-2022 | Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors. | Lopci, E; Aide, N; Dimitrakopoulou-Strauss, A; Dercle, L; Iravani, A; Seban, R D; Sachpekidis, C; Humbert, O; Gheysens, O; Glaudemans, A W J M; Weber, W A; Van den Abbeele, A D; Wahl, R L; Scott, Andrew M ; Pandit-Taskar, N; Hicks, R J |
| 5 | Jan-2024 | Perspectives on technology: To use or to reuse, that is the endoscopic question - a systematic review of single-use endoscopes. | Anderson, S ; Patterson, K; Skolarikos, A; Somani, B; Bolton, D M; Davis, N F |
| 6 | 2021 | Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin. | Scott, Andrew M ; Czernin, Johannes |
| 7 | 14-Aug-2008 | PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. | Scott, Andrew M ; Gunawardana, Dishan H; Kelley, Ben; Stuckey, John G; Byrne, Amanda J; Ramshaw, Jayne E; Fulham, Michael J |
| 8 | 29-Aug-2017 | PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia. | Di Biase, M A; Zalesky, A; O'keefe, G; Laskaris, L; Baune, B T; Weickert, C S; Olver, James S ; McGorry, P D; Amminger, G P; Nelson, B; Scott, Andrew M ; Hickie, I; Banati, R; Turkheimer, F; Yaqub, M; Everall, I P; Pantelis, C; Cropley, V |
| 9 | 1-Jul-2012 | PET in prostate and bladder tumors. | Lee, Sze Ting ; Lawrentschuk, Nathan; Scott, Andrew M |
| 10 | Oct-2015 | PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. | Zanzonico, Pat; Carrasquillo, Jorge A; Pandit-Taskar, Neeta; O'Donoghue, Joseph A; Humm, John L; Smith-Jones, Peter; Ruan, Shutian; Divgi, Chaitanya; Scott, Andrew M ; Kemeny, Nancy E; Fong, Yuman; Wong, Douglas; Scheinberg, David; Ritter, Gerd; Jungbluth, Achem; Old, Lloyd J; Larson, Steven M |
| 11 | Jan-2024 | PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. | Albert, Nathalie L; Galldiks, Norbert; Ellingson, Benjamin M; van den Bent, Martin J; Chang, Susan M; Cicone, Francesco; de Groot, John; Koh, Eng-Siew; Law, Ian; Le Rhun, Emilie; Mair, Maximilian J; Minniti, Giuseppe; Rudà, Roberta; Scott, Andrew M ; Short, Susan C; Smits, Marion; Suchorska, Bogdana; Tolboom, Nelleke; Traub-Weidinger, Tatjana; Tonn, Joerg-Christian; Verger, Antoine; Weller, Michael; Wen, Patrick Y; Preusser, Matthias |
| 12 | 9-Jun-2012 | Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. | Scott, Andrew M ; Mitchell, Paul L R ; O'Keefe, Graeme J; Saunder, Timothy; Hicks, Rodney J; Poon, Aurora M T ; Baum, Charles; Brega, Nicoletta; McCarthy, Timothy J; Toner, Guy C |
| 13 | 2021 | Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics. | Scott, Andrew M ; Bodei, Lisa |
| 14 | 2000 | Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans. | De Boer, R H; Roskos, L K; Cheung, E ; Fox, S; Basser, R L; Marty, J; Begley, C G; Cebon, Jonathan S |
| 15 | 1-Jun-2021 | A Phase 1 and Biodistribution Study of ABT-806i, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. | Gan, Hui K ; Burge, Matthew; Solomon, Benjamin; Lee, Sze Ting ; Holen, Kyle D; Zhang, Yumin; Ciprotti, Marika; Lee, F T; Manusinghe, Wijth; Fischer, Judee; Ansell, Peter; Fox, Gerard; Xiong, Hao; Reilly, Edward B; Humerickhouse, Rod; Scott, Andrew M |
| 16 | 19-Nov-2005 | A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. | Gan, Hui K ; Mitchell, Paul L R ; Galettis, Peter; Davis, Ian D; Cebon, Jonathan S ; de Souza, Paul; Links, Matthew |
| 17 | Aug-2022 | A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. | Gan, Hui K ; Parakh, Sagun ; Lee, Fook-Thean; Tebbutt, Niall C ; Ameratunga, Malaka; Lee, Sze Ting ; O'Keefe, Graeme J; Gong, Sylvia J; Vanrenen, Christine; Caine, Jaren; Giovannetti, Mara; Murone, Carmel ; Scott, Fiona E; Guo, Nancy; Burvenich, Ingrid J G; Paine, Cameron; Macri, Mary J; Kotsuma, Masakatsu; Senaldi, Giorgio; Venhaus, Ralph; Scott, Andrew M |
| 18 | 2024 | A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. | Lin, Chia-Chi; Garralda, Elena; Schöffski, Patrick; Hong, David S; Siu, Lillian L; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel Sw; Cassier, Philippe A; Sarantopoulos, John; Weickhardt, Andrew J ; Carvajal, Richard D; Spratlin, Jennifer; Esaki, Taito; Rolland, Fréderic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L; Askoxylakis, Vasileios; De Braud, Filippo |
| 19 | 13-Oct-2009 | Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. | Herbertson, Rebecca A; Tebbutt, Niall C ; Lee, Fook-Thean; MacFarlane, David J; Chappell, Bridget; Micallef, Noel; Lee, Sze-Ting; Saunder, Timothy; Hopkins, Wendie; Smyth, Fiona E; Wyld, David K; Bellen, John; Sonnichsen, Daryl S; Brechbiel, Martin W; Murone, Carmel ; Scott, Andrew M |
| 20 | 1-Jun-2007 | A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. | Scott, Andrew M ; Tebbutt, Niall C ; Lee, Fook-Thean; Cavicchiolo, Tina; Liu, Zhanqi; Gill, Sanjeev; Poon, Aurora M T ; Hopkins, Wendie; Smyth, Fiona E; Murone, Carmel ; MacGregor, Duncan; Papenfuss, Anthony T; Chappell, Bridget; Saunder, Timothy H; Brechbiel, Martin W; Davis, Ian D; Murphy, Roger; Chong, Geoffrey ; Hoffman, Eric W; Old, Lloyd J |
